Vanguard Group Inc. Has $979.18 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Vanguard Group Inc. grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,961,687 shares of the company's stock after purchasing an additional 521,204 shares during the quarter. Vanguard Group Inc. owned approximately 9.60% of Vaxcyte worth $979,184,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC grew its stake in Vaxcyte by 23.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after buying an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. grew its position in shares of Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock worth $992,914,000 after acquiring an additional 485,436 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Vaxcyte in the 3rd quarter worth about $41,114,000. Franklin Resources Inc. lifted its position in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after purchasing an additional 324,560 shares during the last quarter. Finally, Maverick Capital Ltd. boosted its stake in Vaxcyte by 41.9% during the 3rd quarter. Maverick Capital Ltd. now owns 976,249 shares of the company's stock valued at $111,556,000 after purchasing an additional 288,341 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PCVX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They set a "buy" rating and a $135.00 target price on the stock. Finally, Guggenheim reissued a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $147.50.

Vaxcyte Stock Performance

Shares of PCVX stock traded down $31.70 during mid-day trading on Monday, hitting $37.76. 13,995,362 shares of the stock traded hands, compared to its average volume of 1,032,557. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of -8.21 and a beta of 1.02. The company's 50-day simple moving average is $80.07 and its 200-day simple moving average is $92.37. Vaxcyte, Inc. has a twelve month low of $30.29 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. Analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares of the company's stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,250 shares of company stock worth $3,840,018 in the last ninety days. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.